Project Grant R44NS143521
Award Date
5/9/25
Completion Date
4/30/27
Dollars Obligated
$1.3M
Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Synapticure Inc. (G9QUJCDRVYB7)
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $1,540,579 to the Regenerative Research Foundation to develop and validate a novel human cell-based model for studying frontotemporal dementia (FTD) caused by mutations in the MAPT gene. The key objectives are to generate a 3D cellular model incorporating cerebral cortex, striatum,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders federal grant program (CFDA 93.853), is funding the development and optimization of a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The award aims to demonstrate a progressive ALS/FTD-like phenotype using aged mouse cohorts and validate the animal findings through...
The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, awarded a $1,138,538 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Mayo Clinic Jacksonville, a nonprofit healthcare organization, to conduct research on the molecular mechanisms and therapeutic interventions related to frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The research aims to explore the...
This Project Grant award, R21AG094047, was provided by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866). The $442,750 award, with a period of performance from May 2025 to April 2027, supports research by Case Western Reserve University (CWRU) to develop synthetic replicas of TDP-43 protein filaments associated with frontotemporal dementia and amyotrophic lateral sclerosis. The goal is to establish an experimental model for generating these...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $2,147,016 to Neurodex Inc. to advance the development of a novel blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and related dementias....
This $459,525 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Aperture Therapeutics, Inc. aims to rapidly discover a novel oligonucleotide therapeutic for direct modulation of a genetically validated target involved in pathologic neuroinflammation. The project leverages Aperture Therapeutics' high-throughput induced pluripotent stem cell (iPSC) platform with diverse genetic models of frontotemporal dementia (FTD) to provide robust functional evidence...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is intended to develop a novel blood-based diagnostic test for the early diagnosis and classification of frontotemporal lobar degeneration (FTD). The $638,854 award to Virtici LLC, a for-profit biomedical research company in Seattle, Washington, will fund the following key objectives: 1)...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $427,625.00 to support research on using directly converted neurons as a novel cellular model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The award will enable The Washington University in St. Louis to investigate neurodegenerative...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This federal Project Grant award of $432,802.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to identify gene expression changes linked to TAR DNA-binding protein 43 (TDP-43) pathology in C9ORF72 frontotemporal dementia (C9 FTD) using Drosophila and human iPSC-derived cortical neuron models. The research aims to cross-validate candidate...